Our Pipeline

Changing kidney disease treatment, for good

We have a robust pipeline of novel, precision medicine product candidates targeting kidney diseases with significant unmet medical need.
Program
Indication
Discovery
IND-Enabling Studies
Phase 1
Phase 2
Phase 3

GFB-887

TRPC5-Rac1-Mediated Kidney Diseases

GFB-887

GFB-887 for Focal Segmental Glomerulosclerosis and Other Rac1-Mediated Kidney Diseases

GFB-887 is a podocyte-targeting, small molecule TRPC5i designed specifically to treat patients with kidney diseases characterized by an over-activation of the TRPC5-Rac1 pathway.

Learn more about GFB-887

Development Status

GFB-887 is currently in a Phase 2 clinical trial for TRPC5-Rac1-mediated kidney diseases.

Rights

GFB-024

CB1-Mediated Subset of DN Caused by SIRD

GFB-024

GFB-024 for Subset of DN caused by Severe Insulin Resistant Diabetes (SIRD)

GFB-024 is a peripherally restricted CB1 inverse agonist monoclonal antibody, which we believe will benefit a subset of people with DN whose disease is caused by SIRD.

Learn more about GFB-024

Development Status

Investigational New Drug (IND)-enabling studies

Rights

New TRPC5 Inhibitors

TRPC5-Rac1-Mediated DN

New TRPC5 Inhibitors

Leveraging our expertise in TRPC5 biology and chemistry, we are developing follow-on compounds to our lead precision medicine product candidate, GFB-887, with differentiating attributes intended for broad market indications, such as DN. We believe that our novel structural insights enhance our understanding of TRPC5 inhibitor binding with TRPC channels, which will enable us to design desirable compounds more efficiently and accelerate our path to IND. Patients with DN are typically treated with a combination of multiple drugs and the compounds that we have discovered to date are being optimized to reduce risk of drug-to-drug interactions with the major drug classes used to treat diabetes. Additionally, we aim to design new compounds that are restricted to peripheral tissues. Molecules from our lead series have been observed in preclinical studies to be highly potent, metabolically stable, and, like GFB-887, orally available.

Development Status

Drug Discovery

Rights